Showing 7541-7550 of 8649 results for "".
- SIFI Initiates Patient Enrollment in Phase 2 Trial Evaluating Pro-Ocular in Dry Eye Diseasehttps://modernod.com/news/sifi-initiates-patient-enrollment-in-phase-2-trial-evaluating-pro-ocular-in-dry-eye-disease/2479120/SIFI announced the enrollment of the first patients in the ProGIFT trial, which aims to evaluate the safety and efficacy of Pro-ocular, a progesterone based topical gel in patients with dry eye disease (DED). P<
- Nicox’s NCX 4251 Mississippi Phase 2b Blepharitis Trial Reaches 50% Enrollmenthttps://modernod.com/news/nicoxs-ncx-4251-mississippi-phase-2b-blepharitis-trial-reaches-50-enrollment/2479109/Nicox SA announced that 102 patients in the NCX 4251 Mississippi phase 2b blepharitis clinical trial have now been randomized out of a target of 200, with topline results currently on track to be announced during Q4 2021. “Achievement of 50% enrollment in this phase 2b trial of NCX 4251 in
- Market Scope: US Cataract Pharmaceuticals Evolve in Drug Deliveryhttps://modernod.com/news/market-scope-us-cataract-pharmaceuticals-evolve-in-drug-delivery/2479107/US cataract surgeons showed a preference for incremental improvement in drug delivery over revolutionary change in the first full year for three new corticosteroid products to manage inflammation and pain after cataract surgery, according to a Market Scope report. The products hit the mark
- Johnson & Johnson Vision Receives FDA Clearance and CE Mark for Veritas Vision Systemhttps://modernod.com/news/johnson-johnson-vision-receives-fda-clearance-and-ce-mark-for-next-generation-phacoemulsification-machine-veritas-vision-system/2479100/Johnson & Johnson Vision announced the FDA 510(k) clearance and CE mark of its next-generation phacoemulsification device, the Veritas Vision System. The phaco system features technologies that allow surgeons to guide through any lens density with less surge and more stability. The new system
- EyeCare Partners Promotes David Clark to Chief Executive Officerhttps://modernod.com/news/eyecare-partners-promotes-david-clark-to-chief-executive-officer/2479099/EyeCare Partners LLC announced the promotion of David A. Clark to chief executive officer, effective immediately. Mr. Clark joined EyeCare Partners as president in July 2020 after 20 years with MEDNAX Inc., where he was most recently ch
- Mount Sinai Ophthalmologists use Breakthrough Imaging to Understand Eye Damage from Rare Congenital Retinal Diseasehttps://modernod.com/news/mount-sinai-ophthalmologists-use-breakthrough-imaging-to-understand-eye-damage-from-rare-congenital-retinal-disease/2479098/Researchers from New York Eye and Ear Infirmary of Mount Sinai used adaptive optics–retinal imaging technology that allows clinicians to examine microscopic structures of the eye in living patients with extreme detail in real time–to analyze and better understand a rare retinal disease called “fu
- Next-Generation COVID Vaccines Have Many Different Targetshttps://modernod.com/news/next-generation-covid-vaccines-have-many-different-targets/2479094/Vaccine developers are monitoring the durability of the immune response of current COVID vaccines while racing against variants to provide more options for protection, no matter what happens next in the pandemic, according to a Medscape report
- Nanodropper Completes $1.4 Million Seed Funding Roundhttps://modernod.com/news/nanodropper-completes-1-4-million-seed-funding-round/2479092/Nanodropper, which is making a first-of-its-kind eyedrop bottle adaptor that reduces eyedrop size, recently completed a $1.4 million seed round. Golden Seeds, a recognized leader in the movement to accelerate funding to women en
- Gyroscope Therapeutics Files Registration Statement for Proposed Initial Public Offering in the United Stateshttps://modernod.com/news/gyroscope-therapeutics-files-registration-statement-for-proposed-initial-public-offering-in-the-united-states/2479087/Gyroscope Therapeutics announced it has filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering (IPO) in the United States. All American Depositary Shares (ADSS) to be sold in the proposed IPO will be
- Pfizer CEO Predicts Third COVID-19 Vaccine Booster “Likely” Needed Within Yearhttps://modernod.com/news/pfizer-ceo-predicts-third-covid-19-vaccine-booster-likely-needed-within-year/2479086/Pfizer CEO Albert Bourla believes it will probably be necessary for people to receive yet another dose of COVID-19 vaccine within a year of being fully vaccinated in order to stave off infection, according to recent taped comments that were made public on Thursday. “There will be likely a n